Long-Term Follow-up Protocol for Subjects Treated With JCAR015
Latest Information Update: 06 Jun 2022
Price :
$35 *
At a glance
- Drugs JCAR 015 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Juno Therapeutics
- 02 Jun 2022 Status changed to completed.
- 08 Mar 2021 Planned number of patients changed from 500 to 38.
- 08 Mar 2021 Planned End Date changed from 1 Sep 2032 to 30 Sep 2032.